Delivery of RNA to trigger multiple immune pathways
Andrew Geall, Littleton, MA (US); Katrin Ramsauer, Vienna (AT); Gillis Otten, Rowley, MA (US); and Christian Walter Mandl, Lexington, MA (US)
Assigned to GlaxoSmithKline Biologicals SA, Rixensart (BE)
Filed by GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Filed on Dec. 13, 2022, as Appl. No. 18/065,069.
Application 15/725,858 is a division of application No. 13/808,085, granted, now 9,801,897, issued on Oct. 31, 2017, previously published as PCT/US2011/043104, filed on Jul. 6, 2011.
Application 18/065,069 is a continuation of application No. 17/511,762, filed on Oct. 27, 2021, granted, now 11,596,645.
Application 17/511,762 is a continuation of application No. 16/512,541, filed on Jul. 16, 2019, granted, now 11,291,682, issued on Apr. 5, 2022.
Application 16/512,541 is a continuation of application No. 15/725,858, filed on Oct. 5, 2017, granted, now 10,532,067, issued on Jan. 14, 2020.
Claims priority of provisional application 61/361,789, filed on Jul. 6, 2010.
Prior Publication US 2023/0117413 A1, Apr. 20, 2023
1. A composition comprising lipid particles and messenger ribonucleic acid (mRNA) molecules; the mRNA molecules comprising: (i) a 5′ cap nucleoside, (ii) a first 5′ ribonucleoside, (iii) a triphosphate bridge, and (iv) a sequence that encodes an influenza A virus immunogen; the first 5′ ribonucleoside comprising a 2′-methylated ribose; the 5′ cap nucleoside being linked 5′-to-5′ to the first 5′ ribonucleoside by the triphosphate bridge; the lipid particles comprising: (a) a polyethylene glycol-ylated lipid, (b) cholesterol, (c) an anionic phospholipid or a zwitterionic phospholipid, and (d) a cationic lipid comprising a tertiary amine; and the lipid particles encapsulating at least half of the mRNA molecules.